SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

June 27, 2012 07:00 ET

Implant Sciences' Quantum Sniffers Open New Market in Mobile Air Freight Screening

WILMINGTON, MA--(Marketwire - Jun 27, 2012) -  Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold a follow-on order for its Quantum Sniffer™ H150 handheld explosives trace detector to First Class Zollservice und Transportvermittlungs GmbH, a current customer in Germany. The sale was made through Implant Sciences' Hamburg-based distributor, D-TeC System Consulting GmbH, a products and consulting business that supports a wide range of security markets including aviation and logistics.

First Class Zollservice has provided professional cargo management and transport services to its client base since 1992. The company has recently expanded its air cargo security capabilities with a mobile screening service that provides explosives trace detection on a fee-per-piece basis for air freight forwarders. This service utilizes a Quantum Sniffer installed in a vehicle that is driven to freight forwarding facilities to perform the cargo screening.

Holger Hille, General Manager of First Class Zollservice, added, "We implemented the first QS-H150 in our newly launched mobile screening service late last year. Implant Sciences' portable trace detector has performed extremely well and we are seeing growing demand for our mobile service, leading to our second QS-H150 order. In Germany we have strict regulations regarding the transportation of equipment that uses radioactive materials. With its advanced design, the QS-H150 has opened a new market for us."

"First Class Zollservice has been very innovative in identifying a new niche market which caters to smaller shippers for whom purchasing screening equipment is not cost effective. In providing screening as a service, this company is offering better economics to a new customer base," stated Implant Sciences' Vice President of Global Sales and Marketing, Dr. Darryl Jones. "We believe that the non-radioactive design of our Quantum Sniffer trace detectors offers a number of opportunities in which we can gain further traction globally."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact